Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEN 1309

Next Previous
Drug Profile

MEN 1309

Alternative Names: MEN-1309; MEN1309/OBT076; OBT 076

Latest Information Update: 10 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioTherapeutics
  • Developer Agenus; Groupe Oncologie Radiotherapie Tete et Cou; Menarini; Oxford BioTherapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adenoid cystic carcinoma; Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 10 Jun 2025 3898048- Updated KDM, AE, TT, added HE
  • 09 May 2025 Groupe Oncologie Radiotherapie Tete et Cou terminates the phase-I trial in Adenoid cystic carcinoma (Combination therapy, Monotherapy, Metastatic disease, Recurrent) in France (IV, Infusion) due to toxicity (NCT05930951)
  • 25 Apr 2025 Efficacy and adverse events data from a phase Ib trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top